Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Limited Deoxynucleoside Pools Underlie Cisplatin-Induced Neurotoxicity.

Cancer discovery·2026
Same journal

Chemically Induced Skin Tumors Arise from Upper Hair Follicle Stem Cells.

Cancer discovery·2026
Same journal

Retraction Casts Doubt on Timing Effects of Immunotherapy.

Cancer discovery·2026
Same journal

mtDNA Lineage Tracing Reveals Monocyte Fate Bias Prior to Tumor Infiltration.

Cancer discovery·2026
Same journal

Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Cancer discovery·2026
Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026

Related Experiment Video

Updated: Feb 16, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K

Value in Using CAR T Cells for DLBCL

    Cancer Discovery
    |December 17, 2017
    PubMed
    Summary

    Tisagenlecleucel, a CD19-targeting CAR T-cell therapy, showed durable responses in diffuse large B-cell lymphoma patients. The JULIET trial found significant complete and partial responses at three and six months post-treatment.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Hematology

    Background:

    • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
    • Relapsed and refractory DLBCL presents significant treatment challenges.
    • CAR T-cell therapy offers a novel approach for refractory hematologic malignancies.

    Purpose of the Study:

    • To evaluate the efficacy and durability of tisagenlecleucel in patients with relapsed/refractory DLBCL.
    • To assess response rates at multiple time points following CAR T-cell infusion.
    • To analyze the safety and tolerability profile of tisagenlecleucel in this patient population.

    Main Methods:

    • Phase II clinical trial (JULIET) design.
    • Enrollment of adult patients with relapsed/refractory DLBCL.

    More Related Videos

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.1K
    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K

    Related Experiment Videos

    Last Updated: Feb 16, 2026

    A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
    12:16

    A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

    Published on: October 16, 2018

    15.6K
    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.1K
    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K
  • Administration of tisagenlecleucel (a CD19-targeting CAR T-cell therapy).
  • Assessment of objective response rates (ORR) including complete response (CR) and partial response (PR) at 3 and 6 months.

    • Main Results:

    • At 3 months post-infusion, 32% of patients achieved complete response (CR) and 6% achieved partial response (PR).
    • At 6 months post-infusion, CR rates were sustained at 30%, with 7% PR.
    • These findings indicate sustained efficacy of tisagenlecleucel in this challenging patient group.

    Conclusions:

    • Tisagenlecleucel demonstrates durable efficacy in patients with relapsed/refractory DLBCL.
    • CAR T-cell therapy represents a viable treatment option for patients with refractory disease.
    • The JULIET trial supports the role of tisagenlecleucel in the treatment landscape of DLBCL.